ARTICLE | Clinical News
NY-ESO-1 immunotherapy: Therion began a dose-ranging European Phase I trial of its NY-ESO-1 immunotherapy, which uses rV-NY-ESO-1 and rF-NY-ESO-2 in a prime-boo
January 7, 2002 8:00 AM UTC
Therion Biologics Corp., Cambridge, Mass. Product: NY-ESO-1 immunotherapy Business: Cancer Therapeutic category: Immune stimulation Target: NY-ESO-1-expressing tumor cells Description: Recombinant vac...